Form 4: Xeris Biopharma Legal Officer Sells Shares Under 10b5-1 Plan

Xeris Biopharma's Chief Legal Officer, Beth Hecht, sold 16,667 shares of common stock for a weighted average price of $7.4264 per share under a Rule 10b5-1 plan.

Summary

• Beth Hecht, Chief Legal Officer and Corporate Secretary of Xeris Biopharma Holdings, Inc., reported a sale of common stock.
• The transaction involved the disposition of 16,667 shares of common stock.
• The shares were sold on January 2, 2026, at a weighted average price of $7.4264 per share.
• The sale was executed pursuant to a pre-arranged Rule 10b5-1 trading plan.
• Individual sales prices for the shares ranged from $7.280 to $7.740 per share.
• Following the transaction, Beth Hecht beneficially owns 1,308,103 shares of common stock directly.
• This beneficial ownership includes 2,627 shares acquired on June 30, 2025, and 1,967 shares acquired on December 31, 2025, under the issuer's 2018 Employee Stock Purchase Plan.

Sentiment

Score: 5

Explanation: The sale of shares by an insider is generally viewed neutrally when conducted under a pre-arranged Rule 10b5-1 plan, as it suggests a planned liquidity event rather than a reaction to new, negative company-specific information. The reporting person also retains a substantial holding.

Positives

• The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned sale rather than a reaction to new, undisclosed information.
• The reporting person continues to hold a significant number of shares (1,308,103), demonstrating continued alignment with shareholder interests.

Negatives

• An insider sale, even under a 10b5-1 plan, can sometimes be perceived as a lack of confidence by some investors, though this is mitigated by the pre-planned nature.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing.

Industry Context

This filing is a routine insider transaction report and does not provide information to analyze broader industry trends or the competitive landscape for Xeris Biopharma Holdings, Inc.

Stakeholder Impact

• Shareholders: The sale by a key executive, even under a 10b5-1 plan, could be interpreted by some as a slight negative signal, though the pre-planned nature mitigates this. The retained significant holding suggests continued alignment with shareholder interests.

Key Dates

Recommendation

The insider sale by the Chief Legal Officer, while a disposition of shares, was conducted under a Rule 10b5-1 trading plan. This pre-scheduled nature typically reduces the market's interpretation of the sale as a negative signal regarding the company's immediate prospects. The executive also retains a substantial beneficial ownership, indicating continued vested interest. Without additional financial or operational updates, this routine insider transaction does not warrant a change in investment posture.

Keywords

Xeris Biopharma Holdings, Inc., XERS, insider trading, Form 4, stock sale, Rule 10b5-1, Beth Hecht, Chief Legal Officer, corporate secretary, common stock